Gilead Sciences Total Revenue: $29.44B Founded Year: 1987 Total Employees: 17,000 Headquarters: California, United States Market Cap: $176.37B Stock Exchange: NASDAQ Gilead is a global biopharma company focused on antivirals and specialty therapeutics, with leadership in HIV, oncology, and liver diseases - anchored by a strong antiviral franchise and an expanding oncology portfolio
It plays a crucial role in neutralizing free radicals generated by factors like sun exposure, pollution, and lifestyle choices
We think this means that GLP-1 receptor agonist drug use could continue to grow in the next 5 years, to a point where we could see at least 5% of the population of most advanced and upper-middle income countries using them routinely
Keratinocytes and cytokines
This is the most anticipated part
Nevertheless, the smaller sample sizes limit the statistical power to detect a relatively uncommon event like retinopathy worsening